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Abstract: Neutrophils provide first-line defense against infections and are potent effectors in innate and adaptive 
immunity. Recently neutrophils have been shown to play important roles in multiple antitumor reactions. A subset 
of mature neutrophils in human systemic inflammation has been identified as a unique circulating population of 
myeloid cells, which is capable of inhibiting T cell responses. These neutrophils show unique immunophenotype 
(CD11c bright/CD62L dim/CD11b bright/CD16 bright). This study reports detection of mature neutrophils with 
similar immunophenotype in the peripheral blood samples of cancer patients using flow cytometry analysis. This 
population of neutrophils is not detected in peripheral blood samples of normal controls. Thus this finding suggests 
the involvement of mature neutrophils in antitumor immunity.
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Introduction
Neutrophils are the most abundant leukocytes 
in the circulating blood. They provide the first-
line defense against infection and are potent 
effectors of inflammation [1]. In addition, neu-
trophils also are engaged in a complex cross-
talk with immune and endothelial cells that 
bridges innate and adaptive immunity [1, 2]. 
Recent studies have suggested that neutro-
phils are active in immunosurveillance against 
several tumors [3-6]. Even though many 
aspects of their biology have been thoroughly 
investigated, a deep insight into the biological 
role of neutrophils in antitumor reactions is still 
needed. Neutrophils could be a perfect weapon 
for the suppression of tumor growth.
Recent studies have identified myeloid-derived 
suppressor cells (MDSC) that are potent sup-
pressors of tumor immunity and therefore a sig-
nificant impediment to cancer immunotherapy 
[7]. MDSC accumulate in the blood, lymph 
nodes, and bone marrow and at tumor sites in 
most patients and experimental animals with 
cancer and inhibit both adaptive and innate 
immunity. MDSC are a heterogeneous family of 
myeloid cells and they are able to suppress T 
cell activation. In cancer patients, MDSC are 
typically CD11b+ CD33+ CD34+ CD14- HLA-
DR- and can vary in their expression of CD15 
and other markers [8-11]. The variation in 
MDSC phenotype is consistent with the concept 
that MDSC are a diverse family of cells that are 
in various intermediate stages of myeloid cell 
differentiation [7].
Pillay et al identified a subset of mature neutro-
phils in human systemic inflammation as a 
unique circulating population of myeloid cells, 
which is capable of inhibiting T cell responses 
[12]. These neutrophils show unique immuno-
phenotype (CD11c bright/CD62L dim/CD11b 
bright/CD16 bright). These cells are observed 
in humans in vivo during acute systemic inflam-
mation induced by endotoxin challenge or by 
severe injury. Local release of hydrogen perox-
ide from the neutrophils into the immunological 
synapse between the neutrophils and T cells 
mediated the suppression of T cell proliferation 
and required neutrophils expression of the inte-
grin Mac-1.
The goal of our study is to evaluate whether the 
similar subset of neutrophils can be detected in 
peripheral blood samples of cancer patients, in 
comparison to normal non-cancer patients.
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Materials and methods
Peripheral blood samples were retrieved from 
the hematology laboratory at the Department 
of Pathology, UMass Memorial Medical Center, 
Worcester, MA. This study was approved by the 
UMass Memorial Medical Center Institutional 
Review Board.
Samples and patients
Peripheral blood samples were retrieved from 
31 cancer patients prior to surgery, radiation, 
or any systemic chemotherapy. 31 samples 
from normal healthy patients with routine phys-
ical examination were served as controls. There 
were also 10 samples from patients undergo-
ing surgeries for benign diseases.
Flow cytometry analysis
For all samples, five-color flow cytometry was 
performed on Beckman Coulter FC-500 instru-
ments (Beckman Coulter, Inc, Miami, FL) using 
commercially available reagents. All monoclo-
nal antibodies used in the study were from 
Beckman Coulter, Inc. (Miami, FL) and they 
included monoclonal antibodies directed 
Figure 1. Identification of suppressive neutrophils in peripheral blood samples of cancer patients. A. Neutrophils 
were selected and gated based on CD45 and side scatter. B. A representative histogram from a normal control. C. 
A representative histogram from a cancer patient. D. A representative histogram from a non-cancer surgery patient. 
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against CD45 (clone J. 33, phycoerythrin-Texas 
Red (ECD) conjugated), CD62L (clone DREG56, 
fluorescein isothiocyanate (FITC) conjugated), 
CD16 (clone 3GB, phycoerythrin-cyanine7 
(PC7) conjugated), CD11b (clone Bear1, phyco-
erythrin-cyanine5 (PC5) conjugated), and 
CD11c (clone BU15, phycoerythrin (PE) conju-
gated). 100 µL aliquot of whole blood was incu-
bated with the appropriate amount of titrated 
antibodies for 10 minutes at room temperature 
in the dark. Then 2.0 ml of VersaLyse solution 
was added to each tube and then incubated in 
the dark at room temperature for 15 minutes to 
lyse the red blood cells. Then the tubes were 
centrifuge at 400 x g (1,400 rpm) for 5 minutes 
at room temperature and carefully poured off 
supernatant. Then 1.0 ml of Sheath Fluid was 
added to the tubes and centrifuged at 400 x g 
(1,400 rpm) for 5 minutes at room temperature 
and carefully pour off supernatant. Each cell 
pellet was then resuspended in 500 µL of 
Fixative Solution. Store the samples in the 
refrigerator until they are analyzed on the flow 
cytometer. The instrument alignment, sensitivi-
ties, and spectral compensation were verified 
daily by standards, calibrators, procedural con-
trols, and normal peripheral blood samples 
prior to processing of patient samples. For 
all cases, at least 15,000 cells acquired for 
each case and analyzed by gating on neu- 
trophils.
Figure 2. Comparison of gated 
neutrophil percentages (A), total 
white blood cell percentages (B), 
and absolute counts (C) of sup-
pressive neutrophils in normal 
controls (represented by ■), can-
cer patients (represented by ●), 
and non-cancer surgery patients 
(represented by ▲).
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Cell counts
Total leukocyte counts were counted in whole 
blood using Beckman Coulter LH750 (Beckman 
Coulter, Inc, Miami, FL). Using the percentages 
found by flow cytometry and the absolute leu-
kocyte count, the absolute numbers of circulat-
ing neutrophil subsets were calculated.
Statistical analysis
Data was summarized using means and stan-
dard deviations. Student t tests were applied to 
test for differences between groups (e.g. can-
cer patients vs. normal controls; non-cancer 
surgery patients vs. normal controls; cancer 
patients vs. non-cancer surgery patients). 
Statistical significance for all comparisons was 
based on two-sided comparisons with p < 0.05. 
Confidence interval is 95%. Data are presented 
as mean ± standard error of the mean (SEM).
Results
Normal control samples
In order to obtain an accurate and unbiased 
determination of both percentage and absolute 
number of subsets of neutrophils in patients, 
whole blood flow cytometry analysis was per-
formed using a combination of CD45/CD11b/
CD11c/CD16/CD62L. 31 normal control sam-
ples were analyzed. The neutrophils were gated 
on based on CD45 intensity and side scatter 
(Figure 1A). Then the analysis reveals that most 
of the neutrophils express bright expression of 
CD11b, CD11c, CD16 and CD62L. The popula-
tion of cells with dim expression for CD16 rep-
resents eosinophils and it is not included in 
further measurements. The immune suppres-
sive neutrophils exhibit bright expression of 
CD11b, CD11c, CD16, but dim expression of 
CD62L as documented in a previous paper by 
Pillay et al [12]. This subset of neutrophils sup-
presses lymphocytes activation. A representa-
tive histogram from a normal control is shown 
in Figure 1B. In this example, this subset of 
neutrophils comprises 0.3% of gated neutro-
phils and 0.1% of total white blood cells. The 
absolute count of this subset of neutrophils is 
8/mm3. In 31 normal control patient samples, 
the percentages of this subset of neutrophils in 
gated neutrophils range from 0.3% to 5.1% with 
mean of 1.5% (standard error of the mean 
(SEM): 0.17%) (Figure 2A). The percentages of 
this subset of neutrophils in total white blood 
cells range from 0.05% to 1.2% with mean of 
0.4% (SEM: 0.05%) (Figure 2B). The absolute 
counts of this subset of neutrophils range from 
4/mm3 to 75/mm3 with mean of 28.1/mm3 
(SEM: 3.4/mm3) (Figure 2C).
Identification of immune suppressive neutro-
phils in cancer patients
Peripheral blood samples were retrieved from 
31 cancer patients (mean age 62; range 46-88) 
with newly diagnosed and histologically con-
firmed solid malignancies. In accordance with 
American Joint Committee on Cancer (AJCC) 
Cancer Staging Manual, seventh edition (2010), 
there are 18 patients with stage I/II disease 
and 10 patients with stage III/IV disease. In 
addition, there are 3 patients with glioblastoma 
multiforme (GBM) in the brain, which do not 
have TNM designation. Blood samples collect-
ed from patients with cancers were obtained 
prior to surgery, radiation, or any systemic che-
motherapy. Patient characteristics are detailed 
in Table 1.
In cancer patients, freshly drawn whole blood 
samples were analyzed by flow cytometry anal-
ysis using a combination of CD45/CD11b/
CD11c/CD16/CD62L. The neutrophils were 
Table 1. Cancer patient characteristics in the 
study
Number of patients (n) 31
Mean age in years (range) 62 (46-88)
Gender
    Male 4
    Female 27
Cancer diagnosis
    Colon 1
    Breast 5
    Pancreatic 2
    Lung 1
    Melanoma 1
    Ovarian 8
    Uterine 9
    Brain 3
    Bladder 1
AJCC clinical cancer stage
    I/II 18
    III/IV 10
    Brain cancer 3
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gated on based on CD45 intensity and side 
scatter. Then the analysis reveals that some 
neutrophils express bright expression of 
CD11b, CD11c, CD16 and CD62L. But there is 
increased number of immune suppressive neu-
trophils, which is characterized by bright 
expression of CD11b, CD11c, CD16, but dim 
expression of CD62L. A representative exam-
ple from a cancer patient is showed in Figure 
1C. In this example, this subset of neutrophils 
comprises 87.7% of gated neutrophils and 
10.5% of total white blood cells. The absolute 
count of this subset of neutrophils is 891/mm3. 
In 31 cancer patient samples, the percentages 
of this subset of neutrophils in gated neutro-
phils range from 0.5% to 87.7% with mean of 
26.8% (SEM: 3.95%) (Figure 2A). The percent-
ages of this subset of neutrophils in total white 
blood cells range from 0.4% to 49.9% with 
mean of 10.3% (SEM: 2.36%) (Figure 2B). The 
absolute counts of this subset of neutrophils 
range from 49/mm3 to 9189/mm3 with mean of 
1312/mm3 (SEM: 328.3/mm3) (Figure 2C). This 
finding is statistically significant when com-
pared to normal controls in regards to neutro-
phil percentage (p < 0.0001) (Figure 2). 
However, the cancer stages do not seem to cor-
relate with the number of immune suppressive 
neutrophils detected in peripheral blood 
samples.
Identification of immune suppressive neutro-
phils in non-cancer surgery patients
There were also 10 samples from patients 
undergoing surgeries for benign diseases, 
which include uterine leiomyomata, ovarian 
cystic benign neoplasms, and brain abscess. 
There is also increased number of immune sup-
pressive neutrophils, which is characterized by 
bright expression of CD11b, CD11c, CD16, but 
dim expression of CD62L. A representative 
example is demonstrated in Figure 1D. In this 
example, this subset of neutrophils comprises 
7.4% of gated neutrophils and 2.6% of total 
white blood cells. The absolute count of this 
subset of neutrophils is 73/mm3. In 10 non-
cancer surgery patient samples, the percent-
age of this subset of neutrophils in gated neu-
trophils range from 1.2% to 39.1% with mean of 
18.0% (SEM: 3.92%) (Figure 2A). The percent-
ages of this subset of neutrophils in total white 
blood cells range from 0.1% to 20.4% with 
mean of 10.3% (SEM: 2.36%) (Figure 2B). The 
absolute counts of this subset of neutrophils 
range from 17/mm3 to 2299/mm3 with mean of 
559.8/mm3 (SEM: 222.1/mm3) (Figure 2C). 
This finding is statistically significant when 
compared to normal controls (Figure 2). 
However, when compared to cancer patients, 
the difference is not statistically significant.
Discussion
Pillay et al has reported the identification of a 
mature neutrophil subset with immune sup-
pressive function, which suppresses T cell acti-
vation in a Mac-1-dependent manner [12]. In 
their study, this subset of neutrophils exhibit 
unique immunphenotype of CD11c bright/
CD62L dim/CD11b bright/CD16 bright. They 
have shown that this unique subset of neutro-
phils was detected in patients suffering sys-
temic inflammation. They also demonstrated 
that these neutrophils displayed regulatory 
properties. In various murine models of cancer, 
sepsis, and transplantation, neutrophils were 
found to be part of MDSCs. This heterogeneous 
group of cells, suppressing lymphocyte activa-
tion, consists mainly of immature neutrophils 
and monocytes.
Here our study detects the same neutrophil 
subset in peripheral blood samples from can-
cer patients. Our work is the first to our knowl-
edge to show a distinct neutrophil phenotype 
CD11c bright/CD62L dim/CD11b bright/CD16 
bright in cancer patients. The percentage and 
absolute number of this subset of neutrophils 
is statistically significantly increased in cancer 
patients when compared to normal controls. 
There is also increased number of neutrophils 
in non-cancer surgery patients when compared 
to normal controls. The percentages and abso-
lute numbers of neutrophils seem to be 
increased in cancer patients when compared 
to non-cancer surgery patients, but they are not 
statistically significant.
MDSCs producing high arginase have been 
found in renal cell carcinoma patients [9]. In 
human with metastatic cancer disease, argi-
nase I-mediated suppression of lymphocytes 
was reported [9, 13]. Arginase I depletes the 
microenvironment of L-arginine, which is essen-
tial for various T cell functions. Despite the fact 
that neutrophil-T cell interactions have been 
described in lymphoid organs in mice [14, 15], 
it is still unknown whether human neutrophils 
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enter lymphoid organs and come into close 
contact with T cells. In many acute and chronic 
inflammatory conditions, however, neutrophils 
and T cells are present in the tissues. As neu-
trophilic inflammation frequently results in tis-
sue damage, neutrophil-induced inhibition of T 
cell proliferation might be essential to limit T 
cell activation and, thereby, maintain tolerance 
in these inflammatory conditions. The exact 
role for neutrophils in immune tolerance in 
humans remains to be examined; however, it is 
clear that neutrophil association with solid 
tumors is detrimental for disease outcome, 
possibly through suppressing immunogenic 
antitumor responses.
Our data also corroborated with previous work 
by Diaz-Montero CM et al, which reported that 
circulating MDSC levels in cancer patients of all 
stages are significantly higher when compared 
to normal volunteers [16]. They found that per-
centages and absolute numbers of MDSC 
increased with clinical cancer stage and exten-
sive tumor burden. Their study provided evi-
dence that MDSC is a clinically important medi-
ator of tumor-mediated immune suppression in 
patients with solid tumors. Abnormal accumu-
lation of MDSC is an important mechanism of T 
cell unresponsiveness in cancer patients. 
Future cancer vaccine trials should therefore 
take into account circulating MDSC in patients 
as their presence may significantly decrease 
their clinical effectiveness. Pharmacologic 
strategies to reduce levels of MDSC in patients 
should be tested in future clinical trials. 
However, it is unknown whether reduction of 
MDSC in either number or partial reversal of 
their immunosuppressive properties is possi-
ble in cancer patients and whether this would 
significantly delay tumor progression. This may 
be a clinically viable strategy to significantly 
improve the efficacy of immunotherapy in can-
cer patients.
In conclusion, we provide evidence of identifica-
tion of a unique subset of neutrophils in periph-
eral blood samples from cancer patients, which 
have been shown to have immune suppressive 
capacity. Understanding of the functions of this 
neutrophil subset in human cancers might pro-
vide novel therapeutic strategies to target 
immune suppression in inflammation and 
cancer.
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